In Brazil, there has been intense discussion on the importance of protecting data package for the research and development of new medicines. The subject has gained additional attention given the absence of a protection period in the country. As we will see throughout the study, now published by INTERFARMA, most of the surveyed countries have an express protection period for the data package.
Para baixar o PDF, Click aqui.